To evaluate whether IgE antibodies may engage with FcεRs to engender Fc-mediated effector functions against HER2+tumors, we analyzed publicly available data sets.22 23 HER2 overexpression was confirmed in ovarian and breast tumors, in the latter it was associated with reduced overall survival (OS) following systemic treatment (endocrine therapy and chemotherapy) (figure 1A). Here, ERBB2 is linked to breast neoplasm.